In the Original Investigation entitled “Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial,”1 published in the September 26, 2017, issue of JAMA, there were a few errors in Table 4 and in Figures 2 and 3. In Figure 2, the log-rank P value should be .04. Figure 3 was revised to fix the Kaplan-Meier plot and the No. at patients at each time point, which were slightly off. In addition, the log-rank P value should be .09. In Table 4, for the “genotype-guided warfarin dosing” group, row for “absolute difference between algorithms in predicted warfarin use,” high-risk group (≥1.0 mg/d), the mean PTTR remained at 55.3% but the 95% CI was changed to “52.7% to 57.9%.” This article was corrected online.
References
- 1.Gage BF, Bass AR, Lin H, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA. 2017;318(12):1115-1124. [DOI] [PMC free article] [PubMed] [Google Scholar]